Seven-Site Facial Contouring with Botulinum Toxin Alone: A Practical Framework.
- 1You&Chung Skin Clinic, Seoul 06062, Republic of Korea.
- 2V&MJ Dermatology Clinic, Seoul 06021, Republic of Korea.
Abstract
More aesthetic patients now ask for changes in facial contour: a smaller face, a sharper jawline, and less sagging. Botulinum toxin (BoNT) is best known as a treatment for wrinkles, but it can also be used for modifying facial contour. With BoNT alone, a wide face can be made narrower, a heavy lower face can be made lighter, sagging on the jawline can be reduced, and a short chin can be corrected. Many physicians already do this, but each site is taught and studied on its own. This review brings the sites together under the name "contouring BoNT". It describes seven sites: five muscles (masseter, temporalis, platysma, depressor anguli oris, mentalis) and two salivary glands (parotid, submandibular). The seven sites work in three ways: reducing the volume of a muscle or gland, removing a downward pull so that the face looks lifted, and relaxing an overactive muscle that changes the shape of the chin. All three serve one goal that patients describe in their own words: a smaller and lifted face. For each site, the review explains what it does to the contour, who is a good candidate, who needs caution, the published dose range and the authors' practice, and which neighboring site changes when the target is treated. It explains which sites are checked together and how each is examined. Two safety points specific to contouring-the immunogenicity of large repeated doses, and salivary gland treatment-are discussed separately. The framework provided is a checklist for assessment, not a rule stating that every patient needs all seven sites to be treated.
Related
- Extratemporal Facial Nerve: Surgical Landmarks, Risk Zones, and a Practical Framework for Safe Dissection
- Muscle- and Gland-Specific Dosing of Botulinum Toxin in Facial Aesthetics: Review of Dose Ranges, Target Depth, Muscle Thickness, and Neuromuscular or Glandular Anatomy.
- Establishing a Dedicated Body Contouring Fellowship: Rationale, Structure, and a Framework for Subspecialty Training.
- Combination of Technologies in Body Contouring: Evidence Mapping and a Decision-Making Algorithm
- Rechallenge After Immune Checkpoint Inhibitors Myocarditis: Evidence and a Practical Framework
BibTeX
@article{chung2026sevensite,
title = {{Seven-Site Facial Contouring with Botulinum Toxin Alone: A Practical Framework.}},
author = {Woon-Kyong Chung and Min Joo Kim},
journal = {Toxins},
year = {2026},
month = oct,
doi = {10.3390/toxins18100448},
url = {https://europepmc.org/article/MED/42931541},
note = {CC BY},
}
RIS
TY - JOUR
TI - Seven-Site Facial Contouring with Botulinum Toxin Alone: A Practical Framework.
AU - Woon-Kyong Chung
AU - Min Joo Kim
PY - 2026
DA - 2026/10/15
JO - Toxins
DO - 10.3390/toxins18100448
UR - https://europepmc.org/article/MED/42931541
AB - More aesthetic patients now ask for changes in facial contour: a smaller face, a sharper jawline, and less sagging. Botulinum toxin (BoNT) is best known as a treatment for wrinkles, but it can also be used for modifying facial contour. With BoNT alone, a wide face can be made narrower, a heavy lower face can be made lighter, sagging on the jawline can be reduced, and a short chin can be corrected. Many physicians already do this, but each site is taught and studied on its own. This review brings the sites together under the name "contouring BoNT". It describes seven sites: five muscles (masseter, temporalis, platysma, depressor anguli oris, mentalis) and two salivary glands (parotid, submandibular). The seven sites work in three ways: reducing the volume of a muscle or gland, removing a downward pull so that the face looks lifted, and relaxing an overactive muscle that changes the shape of the chin. All three serve one goal that patients describe in their own words: a smaller and lifted face. For each site, the review explains what it does to the contour, who is a good candidate, who needs caution, the published dose range and the authors' practice, and which neighboring site changes when the target is treated. It explains which sites are checked together and how each is examined. Two safety points specific to contouring-the immunogenicity of large repeated doses, and salivary gland treatment-are discussed separately. The framework provided is a checklist for assessment, not a rule stating that every patient needs all seven sites to be treated.
SN - 2072-6651
ER -